Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Amgen |
---|---|
Information provided by: | Amgen |
ClinicalTrials.gov Identifier: | NCT00352950 |
To determine the dose and schedule of sirolimus when given in combination with panitumumab in adult subjects with Stage IIIB/IV NSCLC
Condition | Intervention | Phase |
---|---|---|
Oncology Non-Small Cell Lung Cancer |
Drug: AMG 954/Panitumumab |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Single Group Assignment, Safety Study |
Official Title: | An Open-Label Clinical Trial Evaluating the Safety and Pharmacodynamics of Sirolimus and Panitumumab in Subjects With Advanced Non-Small Cell Lung Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Responsible Party: | Amgen Inc. ( Global Development Leader ) |
Study ID Numbers: | 20040145 |
Study First Received: | April 6, 2006 |
Last Updated: | December 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00352950 History of Changes |
Health Authority: | United States: Food and Drug Administration |
NSCLC, Lung cancer Panitumumab Sirolimus mTOR Monoclonal antibody |
Thoracic Neoplasms Sirolimus Anti-Infective Agents Immunologic Factors Immunosuppressive Agents Carcinoma Antibodies, Monoclonal Anti-Bacterial Agents Antibodies |
Respiratory Tract Diseases Lung Neoplasms Antifungal Agents Lung Diseases Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Immunoglobulins |
Thoracic Neoplasms Sirolimus Anti-Infective Agents Respiratory Tract Neoplasms Neoplasms by Histologic Type Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Antibiotics, Antineoplastic Immunosuppressive Agents Pharmacologic Actions |
Carcinoma Anti-Bacterial Agents Neoplasms Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Antifungal Agents Therapeutic Uses Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |